What is a 503B outsourcing facility?

What is a 503B outsourcing facility?

• A. A facility that stores drugs for the manufacturer.
• B. A software platform for compounding management.
• C. A facility that compounds sterile drugs and outsources distribution to facilities.
• D. A hospital owning drug inventories.

Answer: (C)

A 503B outsourcing facility is an FDA-regulated compounding operation that produces sterile drug products in bulk and distributes them to healthcare facilities such as hospitals and clinics. Operating under Section 503B of the FD&C Act, these facilities follow current good manufacturing practices, undergo regular FDA inspections, and perform quality testing (like sterility, endotoxin, and potency checks) with proper batch records. They’re designed to provide ready-to-use sterile products to facilities rather than direct-to-patient retail, helping ensure a steady supply of sterile medications that might not be available off the shelf. This isn’t just storage for a manufacturer, nor a software platform for managing compounds, and it doesn’t describe a hospital that owns its own inventories. Instead, it focuses on large-scale sterile compounding and distribution to healthcare facilities under strict regulatory oversight.

A 503B outsourcing facility is an FDA-regulated compounding operation that produces sterile drug products in bulk and distributes them to healthcare facilities such as hospitals and clinics. Operating under Section 503B of the FD&C Act, these facilities follow current good manufacturing practices, undergo regular FDA inspections, and perform quality testing (like sterility, endotoxin, and potency checks) with proper batch records. They’re designed to provide ready-to-use sterile products to facilities rather than direct-to-patient retail, helping ensure a steady supply of sterile medications that might not be available off the shelf.

This isn’t just storage for a manufacturer, nor a software platform for managing compounds, and it doesn’t describe a hospital that owns its own inventories. Instead, it focuses on large-scale sterile compounding and distribution to healthcare facilities under strict regulatory oversight.